Avantax Advisory Services Inc. Has $299,000 Position in Exact Sciences Co. (NASDAQ:EXAS)

Avantax Advisory Services Inc. cut its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 15.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 5,329 shares of the medical research company’s stock after selling 978 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Exact Sciences were worth $299,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in EXAS. Geode Capital Management LLC boosted its stake in shares of Exact Sciences by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after acquiring an additional 7,873 shares in the last quarter. Bellevue Group AG boosted its position in Exact Sciences by 25.1% during the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock worth $98,738,000 after purchasing an additional 290,585 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Exact Sciences by 3.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company’s stock valued at $74,785,000 after purchasing an additional 38,849 shares during the last quarter. Groupama Asset Managment acquired a new position in Exact Sciences during the third quarter valued at approximately $821,000. Finally, ArrowMark Colorado Holdings LLC bought a new position in shares of Exact Sciences in the third quarter valued at approximately $28,608,000. 88.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of research analyst reports. Scotiabank raised their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Piper Sandler lowered their price target on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. BTIG Research boosted their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Barclays lowered their target price on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Finally, TD Cowen upped their price target on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $70.83.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $45.67 on Wednesday. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The stock has a market cap of $8.48 billion, a P/E ratio of -8.20 and a beta of 1.25. The company’s 50-day simple moving average is $50.15 and its 200 day simple moving average is $58.09.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. As a group, research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.